Pot luck: How Trump’s move to liberalize cannabis use could reshape America’s marijuana industry
First, it’s likely to boost medical research into the positive and negative effects of cannabis, including, crucially, the effects of long-term use. When classified under Schedule I, researchers who wanted to study the drug had to be vetted by the federal government. In contrast, studies on Schedule III drugs—considered to have only ‘moderate to low potential for physical and psychological dependence’—don’t have nearly as many restrictions.
Post Comment